Clinical management of a patient with drug dependence who attempted suicide while receiving peginterferon therapy for chronic hepatitis C

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 5, 2009, Pages 387-390

  Fábregas, Bruno Cópio ^a   Moura, Alexandre Sampaio ^a   Marciano, Renata Cristiane ^a   Carmo, Ricardo Andrade ^a   Teixeira, Antônio Lúcio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chronic hepatitis C; Depression; Drug addiction; Interferon alpha; Suicide attempt

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMITRIPTYLINE; CAPTOPRIL; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; LEVOMEPROMAZINE; METFORMIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADD ON THERAPY; ADULT; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; BLOOD EXAMINATION; CASE REPORT; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DRUG DEPENDENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER BIOPSY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT REFERRAL; PHYSICAL EXAMINATION; PSYCHIATRIC TREATMENT; PSYCHIATRIST; RECURRENT DISEASE; SMOKING; SUICIDE ATTEMPT; ADDICTION; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; DEPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SUBSTANCE-RELATED DISORDERS; SUICIDE, ATTEMPTED;

EID: 77953720788     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000500015     Document Type: Article

References (39)

1. World Health Organization. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 2000;75:17-28.
2. Di Bisceglie A.M. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26(3, suppl 1):34S-8S.
3. Kim W.R. The Burden of Hepatitis C in the United States. Hepatology 2002;36(5, suppl 1):30-4S.
4. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa -2a plus ribavirin for chronic hepatitis C vírus infection. N Engl J Med 2002;347:975-82.
5. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
6. Campos L.N., Guimarães M.D.C., Carmo R.A. et al. HIV, syphilis, and hepatitis B and C prevalence among patients with mental illness: a review of the literature. Cad. Saúde Pública 2008;24(Sup 4):S607-S620.
7. Guimarães M.D.C., Campos L.N., Melo A.P.S. et al. Prevalence of HIV, syphilis, hepatitis B and C among adults with chronic mental illness: a national multicenter study in Brazil. Rev Bras Psiquiatr 2009;31(1):43-7.
8. Almeida R.C., Pedroso E.R.P. Vulnerabilidade e exposição a marcadores sorológicos dos vírus da imunodeficiência humana, hepatites B e C, vírus linfotrópico de células T humanas e sífilis em pacientes psiquiátricos internados em hospital público. Rev Assoc Méd Minas Gerais 2004;14:244-50.
9. Chang T.T., Lin H., Yen Y.S., Wu H.L. Hepatitis B and hepatitis C among institutionalized psychiatric patients in Taiwan. J Med Virol 1993;40:170-3.
10. Focaccia R., da Conceição O.J., Sette H.Jr. et al. Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of São Paulo, Measured by a Serologic Survey of Stratified, Randomized and Residence-Based Population. Braz J Infect Dis 1998:2(6):269-84.
11. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric Symptoms Associated with Hepatitis C and Interferon Alpha: A Review. Am J Psychiatry 2000;157:867-76.
12. Lotrich F.E., Rabinovitz M., Gironda P. et al. Depression following pegylated interferon-alpha: Characteristics and vulnerability. Journal of Psychosomatics Research 2007;63:131-5.
13. Singh N., Gayowski T., Wagener M.M. et al. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 1997;11(5 Pt 1):406-11.
14. Lee D.H., Jamal H., Regenstein F.G. et al. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997;42(1):186-91.
15. Osher F.C., Goldberg R.W., McNary S.W. et al. Substance abuse and the Transmission of Hepatitis C Among Persons With Severe Mental Ilness. Psychiatric Services 2003;54(6):842-7.
16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
17. Raison C.L., Broadwell S.D., Borisov A.S. et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005;19(1):23-7.
18. Horikawa N., Yamazaki T., Izumi N. et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. General Hospital Psychiatry 2003;25(1): 34-38.
19. Raison C.L., Borisov A.S., Majer M. et al. Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression. Biol Psychiatry 2008;Sep 16 [Epub ahead of print].
20. Kraus M.R., Schäfer A., Schöttker K. et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008;57:531-36.
21. Capuron L., Raison C.L., Musselman D.L. et al. Association of Exaggerated HPA Axis Response to the Initial Injection of Interferon-Alpha With Development of Depression During Interferon-Alpha Therapy. Am J Psychiatry 2003;160:1342-5.
22. Rifflet H., Vuillemin E., Oberti F. et al. Pulsions suicidaires chez des malades atteints d'hépatite chronique C au cours ou au décours du traitement par l'interféron alpha. Gastroenterol Clin Biol 1998;22:353-57.
23. Janssen H.L.A., Brouwer J.T., Van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3.
24. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 2002;36(5, suppl 1):3S-20S.
25. Knott A., Dieperink E., Willenbring M.L. et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006 Oct;101(10):2254-62.
26. Dollarhide A.W., Loh C., Leckband S.G. et al. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans. J Clin Gastroenterol 2007;41(3):322-28.
27. Robaeys G., Van Vlierberghe H., Matheï C. et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gatroenterol Hepatol 2006;18(2):159-66.
28. Schaefer M., Hinzpeter A., Mohmand A. et al. Hepatitis C Treatment in "Difficult-to-Treat" Psychiatric Patients with Pegylated Interferon-Alpha and Ribavirin: Response and Psychiatric Side Effects. Hepatol 2007:46(4):991-98.
29. Hauser P., Khosla J., Aurora H. et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 2002;7:942-7.
30. Goldman S.L. Successful Treatment of Interferon Alfa-Induced Mood Disorder With Nortriptyline. Psychosomatics 1994:35(4):412-13.
31. Pisani F., Oteri G., Costa C. et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002:25(2):91-110.
32. Dunner D.L., Zisook S., Billow A.A. et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998:59(7):366-73.
33. Alper K., Schwartz K.A., Kolts R.L. et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(4):345-54.
34. Dhuna A., Pascual-Leone A., Langendorf F. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Epilepsia 1991;32(6):890-94.
35. Papakostas G.I., Nutt D.J., Hallett L.A. et al. Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors. Biological Psychiatry 2006;60(12): 1350-55.
36. Laranjeira R., Rassi R., Dunn J. et al. Crack cocaine - a two year follow-up of treated patients. J Addict Dis 2001;20(1):43-48.
37. Ribeiro M., Dunn J., Sesso R. et al. Causes of death among crack cocaine users. Rev Bras Psiquiatr 2006;28(3):196-202.
38. Beato-Filho C.C., Assuncao R.M., Silva B.F. et al. Conglomerados de homicídios e o tráfico de drogas em Belo Horizonte, Minas Gerais, de 1995 a 1999. Cad Saúde Pública 2001;17(5):1163-71.
39. Santos S.M., Barcellos C., Carvalho M.S., Flores R. Detecção de aglomerados espaciais de óbitos por causas violentas em Porto Alegre, Rio Grande do Sul, Brasil, 1996. Cad Saude Publica 2001;17(5):1141-51.